Literature DB >> 12700106

Lymphocytes in allergic bronchopulmonary aspergillosis.

Alan P Knutsen1.   

Abstract

Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease mediated by an allergic late-phase inflammatory response to Aspergillus fumigatus antigens. ABPA is characterized by markedly elevated Aspergillus-specific and total IgE levels and eosinophilia, and manifested by wheezing, pulmonary infiltrates and bronchiectasis and fibrosis, which affect asthmatic and cystic fibrosis (CF) patients. In the pathogenesis of ABPA, A. fumigatus proteases play a role in facilitation of antigen transport across the epithelial cell layer by damaging the epithelial integrity and by a direct interaction with epithelial cell surface receptors, resulting in pro-inflammatory cytokine production and corresponding inflammatory responses. In genetically susceptible asthmatic and CF patients, this leads to an allergic inflammatory response to Aspergillus allergens. A genetic susceptibility is HLA-DR restriction demonstrated by increased frequency of HLA-DR2 and/or DR5 and lack HLA-DQ2. IL-4 plays a central role in the development of allergic inflammatory responses. Our group has demonstrated that ABPA patients have increased sensitivity to IL-4 stimulation and skewing of Th2 responses to Aspergillus allergens in ABPA subjects and a Th1 response in non-ABPA subjects. Interestingly, Aspergillus allergens stimulate IL-10 synthesis is both ABPA and non-ABPA subjects.

Entities:  

Mesh:

Year:  2003        PMID: 12700106     DOI: 10.2741/994

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  8 in total

1.  Airway epithelial indoleamine 2,3-dioxygenase inhibits CD4+ T cells during Aspergillus fumigatus antigen exposure.

Authors:  Sara A Paveglio; Jenna Allard; Samantha R Foster Hodgkins; Jennifer L Ather; Mieke Bevelander; Jana Mayette Campbell; Laurie A Whittaker LeClair; Sean M McCarthy; Albert van der Vliet; Benjamin T Suratt; Jonathan E Boyson; Satoshi Uematsu; Shizuo Akira; Matthew E Poynter
Journal:  Am J Respir Cell Mol Biol       Date:  2010-01-29       Impact factor: 6.914

2.  Distinct CD4+-T-cell responses to live and heat-inactivated Aspergillus fumigatus conidia.

Authors:  Amariliz Rivera; Heather L Van Epps; Tobias M Hohl; Gabrielle Rizzuto; Eric G Pamer
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

3.  The costimulatory molecules CD80, CD86 and OX40L are up-regulated in Aspergillus fumigatus sensitized mice.

Authors:  C S Barrios; B D Johnson; J D Henderson; J N Fink; K J Kelly; V P Kurup
Journal:  Clin Exp Immunol       Date:  2005-11       Impact factor: 4.330

Review 4.  Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.

Authors:  Kana R Jat; Dinesh K Walia; Anju Khairwa
Journal:  Cochrane Database Syst Rev       Date:  2021-09-22

Review 5.  Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis.

Authors:  Alan P Knutsen; Raymond G Slavin
Journal:  Clin Dev Immunol       Date:  2011-04-05

6.  Immunopathology and immunogenetics of allergic bronchopulmonary aspergillosis.

Authors:  Alan P Knutsen
Journal:  J Allergy (Cairo)       Date:  2011-09-28

Review 7.  Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.

Authors:  Kana R Jat; Dinesh K Walia; Anju Khairwa
Journal:  Cochrane Database Syst Rev       Date:  2018-03-18

Review 8.  Current Approach in the Diagnosis and Management of Allergic Bronchopulmonary Aspergillosis in Children With Cystic Fibrosis.

Authors:  Birce Sunman; Dilber Ademhan Tural; Beste Ozsezen; Nagehan Emiralioglu; Ebru Yalcin; Uğur Özçelik
Journal:  Front Pediatr       Date:  2020-10-20       Impact factor: 3.418

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.